| 1 |
28228262 | Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. | 2017 Feb 21 |
2 |
| 2 |
25349305 | Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. | 2015 Jan |
1 |
| 3 |
23544166 | DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases. | 2013 Apr |
1 |
| 4 |
23839309 | Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. | 2013 Sep |
1 |
| 5 |
22653969 | The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. | 2012 Aug |
3 |
| 6 |
22825736 | The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo. | 2012 Oct |
3 |
| 7 |
22134241 | Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. | 2011 Dec 15 |
3 |
| 8 |
20233881 | In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. | 2010 Apr 1 |
2 |